Current and future use of hematopoietic growth factors in cancer medicine (Q33367026)

26 July 2017

1 reference

title

Current and future use of hematopoietic growth factors in cancer medicine (English)

1 reference

26 July 2017

Tariq I Mughal

1

1 reference

26 July 2017

publication date

1 September 2004

1 reference

26 July 2017

published in

Hematological Oncology

1 reference

26 July 2017

volume

22

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

121-134

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

26 July 2017

cites work

1 reference

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

21 January 2018

1 reference

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

21 January 2018

1 reference

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

7 January 2021

1 reference

7 January 2021

Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer

1 reference

7 January 2021

Recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia

1 reference

7 January 2021

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

1 reference

7 January 2021

Haematopoietic growth factors in children with neutropenia

1 reference

7 January 2021

Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness.

1 reference

7 January 2021

Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

1 reference

7 January 2021

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

7 January 2021

The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis

1 reference

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

7 January 2021

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol

1 reference

7 January 2021

Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma

1 reference

7 January 2021

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

1 reference

7 January 2021

Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases

1 reference

7 January 2021

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

1 reference

7 January 2021

The side-effect profile of GM-CSF

1 reference

7 January 2021

Pain assessment of subcutaneous injections

1 reference

7 January 2021

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

7 January 2021

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

1 reference

7 January 2021

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

1 reference

7 January 2021

Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck

1 reference

7 January 2021

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

1 reference

7 January 2021

Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator

1 reference

7 January 2021

Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines

1 reference

7 January 2021

Anaemia in cancer: pathophysiology and treatment.

1 reference

7 January 2021

Frequency and significance of anemia in non-Hodgkin's lymphoma patients.

1 reference

7 January 2021

Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products

1 reference

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

7 January 2021

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

1 reference

7 January 2021

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

7 January 2021

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.

1 reference

7 January 2021

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

1 reference

7 January 2021

Management of anaemia in patients with breast cancer: role of epoetin

1 reference

7 January 2021

Development and characterization of novel erythropoiesis stimulating protein (NESP)

1 reference

7 January 2021

Pure red-cell aplasia and epoetin therapy

1 reference

7 January 2021

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study

1 reference

7 January 2021

Epoetin and pure red-cell aplasia

1 reference

7 January 2021

Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy

1 reference

7 January 2021

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

7 January 2021

Anemia of chronic disease.

1 reference

7 January 2021

Standards of proof, standards of practice, and proof of standards: a tale of two trials.

1 reference

7 January 2021

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

1 reference

7 January 2021

Iron supplement in cancer patients receiving erythropoietin

1 reference

7 January 2021

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.736

1 reference

26 July 2017

1 reference